ArticleJournal of the American Heart Association2025
Serum Metabolites and Heart Failure Risk: MESA and RS.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of circulating metabolites in heart failure (HF) mechanisms and their clinical utility remain unclear. We aimed to examine the associations between serum metabolites and incident HF and assess their performance in improving HF risk prediction.
methodsA total of 23 571 serum metabolomic spectral variables were measured using untargeted proton nuclear magnetic resonance spectroscopy. Participants from MESA (Multi-Ethnic Study of Atherosclerosis; discovery cohort) and RS (Rotterdam Study; replication cohort) with metabolomic data and without prevalent HF at baseline were included. Cause-specific proportional hazards models were used to estimate the associations between metabolomic features and incident HF, with false discovery rate-adjusted
resultsWe included 3942 MESA and 1515 RS participants, with a median of 15 years follow-up. In MESA, 15 metabolites were significantly associated with incident HF (false discovery rate-adjusted
conclusionsFifteen proton nuclear magnetic resonance-measured metabolites were associated with incident HF, but these associations were not independent of diabetes or hypertension. These metabolites provided minimal predictive utility beyond PREVENT-HF equations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.